Consistently, the tumor sizes in the zebrafish HCC primary tumors (KRASG12V+) decreased with Roblitinib treatment, while in the zebrafish HCC primary tumors containing ectopic EZH2 expression, Roblitinib failed to inhibit the HCC cell growth (Fig. 2F and G). The gene discussed is EZH2; the disease is hepatocellular carcinoma.